

The Top 10 Merger & Acquisition Deals in the Biotechnology and Pharmaceutical Industries

Published July 2000
175+ Pages, 35 Exhibits, 20 Company Profiles

By: Kambiz Amdjadi, M.B.A., Christopher D. Herold, Sheetal K. Patel, Enal S. Razvi, Ph.D.

These top-notch deals have set the tone and the foundation for the future of these industries

An eighties-style wave of mergers and acquisitions has made a comeback similar to the music of the same era. It is ironic that in the shadow of the Microsoft anti-trust investigation, numerous industries are consolidating into highly concentrated oligopolies—the biotechnology and pharmaceutical industries are no exception. The current pace of mergers in the pharmaceutical industry will—if left unchecked—produce an industry by 2001 that will be very different from the one in 1999. Approximately eight giant firms will divide 80% of the market and distance themselves from second-tier companies according to all financial indicators. The consolidation in the pharmaceutical industry will have both direct and indirect consequences on biotechnology companies. The acquisition of biotechnology firms by pharmaceutical giants and mergers amongst biotechnology companies themselves is both a consequence of and reason for the consolidation of the pharmaceutical industry.

D&MD's newest Executive Briefing, *The Top 10 Merger & Acquisition Deals in the Biotechnology & Pharmaceutical Industries* examines this trend very closely. This conveniently packaged product can be used to quickly review the mood of the industry in

terms of consolidation. This Briefing delivers to the reader comprehensive information in a well-organized package at a much lower cost than an in-house report. It would take hours of research to gather the essential basic information and countless additional hours to fill in the blanks and develop a framework to think about the issues . . . ***D&MD has done this for you. This is THE Briefing you need to understand the recent industry movements and position your company for success in this consolidating market!***

Unique Features of Top 10 Deals:

- ✓ Overview of the biotechnology landscape in 1999
- ✓ Analysis of market trends in recent mergers and acquisitions
- ✓ Comprehensive profiling of 10 important mergers or acquisitions of 1999
- ✓ In-depth discussion of leading motivations for consolidation in the biotechnology and pharmaceutical industries
- ✓ Detailed explanation of monoclonal antibody technology, which played a prominent role in a number of deals in 1999

Order your copy today!

Contents

Executive Summary

Introduction

- Biotechnology in 1999
- Trends in Mergers and Acquisitions Worldwide
- 1980s-style Merger Fever
- Consolidation in the U.S. and Worldwide
- Pharmaceutical Consolidation
- Anemic Product Pipelines
- Scope of this Briefing
- Glossary of Terms
- Monoclonal Antibody Technology

The Top 10 Deals

- Johnson & Johnson and Centocor
- Warner-Lambert and Agouron
- Celltech and Chiroscience
- Pharmacia & Upjohn (Pharmacia) and SUGEN
- Millennium and LeukoSite
- Gilead and NeXstar
- ALZA and SEQUUS
- MedImmune and U.S. Bioscience
- Corixa and Ribic
- V.I. Technologies and Pentose

For each deal, the following are detailed

- Executive Summary of the Deal
- Profiles of Both Companies
- Products
- Merger/Acquisition Information
- History of Collaborations and Alliances
- Financial Analysis
- Strategic Analysis

No Risk Refund Policy: If you are unsatisfied with this publication, return the book in its original condition within 15 days of receipt and we will send you a full refund by return mail! Please note: Returns cannot be accepted after 15 days.

Data Protection: The information you provide will be held on a database and may be shared with companies in the Informa Group in the US and Internationally. Sometimes your details may be made available to external companies for marketing purposes. If you do not wish your details to be used for this purpose, please write to the Database Manager, One Research Drive, P.O. Box 5195, Westborough, MA 01581-5195.

Drug & Market Development Publications
One Research Drive, P.O. Box 5194
Westborough, MA 01581-5194
Phone: (508) 616-5566 Fax: (508) 616-5544
lwood@drugandmarket.com
www.drugandmarket.com/9012

Order Information

Yes! I wish to order Top 10 Deals (#9012)

<input type="checkbox"/> Best Value:	Qty	Amt
Print & CD Versions for \$2,995.00	_____	\$ _____
<input type="checkbox"/> CD Version for \$1,995.00	_____	\$ _____
<input type="checkbox"/> Print Version for \$1,995.00	_____	\$ _____
Add \$20 for shipping & handling in the US and \$50 for International air delivery		\$ _____
Total Due (MA residents please add 5% sales tax)		\$ _____

Inquiry only. Please send complete table of contents.

Payment Information

Enclosed is a check for payment in full. (Please make checks payable to **DRUG & MARKET DEVELOPMENT.**)

Invoice my organization PO# _____
(Payment or purchase order required prior to shipment.)

Bank Transfer – c/o Fleet Bank NA, 1185 Avenue of the Americas, 3rd Floor, NY, NY 10036; Account #9417820750, Routing #021200339.
(State company name, phone # and report #)

Charge my credit card:

MasterCard Visa American Express

Card # _____

Exp. Date _____

Name (as appears on card) _____

Signature _____

Shipping Information

Name

Title

Company

Department

Address 1

Address 2

City

State

Zip

Country

Telephone

Fax

E-mail

Please sign me up for D&MD's FREE e-mail newsletter